Article

Tolle leads WaveLight's U.S. operations as CEO

Sterling, VA-Wolfgang Tolle has been appointed as the new chief executive officer (CEO) of U.S. operations for WaveLight Inc., a subsidiary of WaveLight AG. In his new post, Tolle will assume responsibility for all business activities at the U.S. based-subsidiary and will report to WaveLight AG's CEO Max Reindl.

Sterling, VA-Wolfgang Tolle has been appointed as the new chief executive officer (CEO) of U.S. operations for WaveLight Inc., a subsidiary of WaveLight AG. In his new post, Tolle will assume responsibility for all business activities at the U.S. based-subsidiary and will report to WaveLight AG's CEO Max Reindl.

Most recently, Tolle was CEO of Launchdreams, a company that specializes in helping international enterprises become established and grow in the United States.

In addition, Tolle has held numerous other executive positions, including CEO, vice president of customer service, and chief technology officer at Cyveillance; president of Virginia's Center for Innovative Technology; and as president of the U.S. office of the German National Research Center for Computer Science.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.